Expression of Insulin-Like Growth Factor-1 Receptor (IGF-1R) and p27^Kip1 in Melanocyte Tumors: A Potential Regulatory Role of IGF-1 Pathway in Distribution of p27^Kip1 between Different Cyclins

References

• Alessandrini A., Chiaur D. S., Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997; 11: 342–345
   PubMedGoogle Scholar
• Baserga R. The insulin-like growth factor-1 receptor: a key to tumor growth?. Cancer Res. 1995; 55: 249–252
   PubMed Web of Science ®Google Scholar
• Baserga R. The IGF-1 receptor and cancer. Endocrine 1997; 7(1)99–102
   PubMed Web of Science ®Google Scholar
• Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-1 receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1997; 1332: 105–126
   PubMed Web of Science ®Google Scholar
• Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Carlberg M., Dricu A., Blegen H., Wang M., Hjertman M., Zickert P., Höög A., Larsson O. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface: evidence for a new link between 3-hydroxy-3-methylglutaryl-Coenzyme A reductase and cell growth. J. Biol. Chem. 1996; 271: 17453–17462
   PubMed Web of Science ®Google Scholar
• Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K. I., Slingerland J. M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 1997; 3: 227–230
   PubMed Web of Science ®Google Scholar
• Dricu A., Carlberg M., Wang M., Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor-1 receptor in induction of apoptosis. Cancer Res. 1997a; 57: 543–548
   PubMed Web of Science ®Google Scholar
• Dricu A., Wang M., Hjertman M., Malec M., Blegen H., Wejde J., Carlberg M., Larsson O. Mevalonate-regulated cell growth in human tumor cells: role of glycosylation of the IGF-1 receptor, prenylation of Ras and expression av c-Myc. Glycobiology 1997b; 7: 625–633
   PubMed Web of Science ®Google Scholar
• Dricu A., Kanter L., Wang M., Nilsson G., Hjertman M., Wejde J., Larsson O. Expression of the insulinlike growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Glycobiology 1999; 9: 571–579
   PubMed Web of Science ®Google Scholar
• Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997; 57: 3381–3385
   PubMed Web of Science ®Google Scholar
• Fredersdorf S., Burns J., Milne A. M., Packham G., Fallis L., Gillett C. E., Royds J. A., Peston D., Hall P. A., Hanby A. M., Barnes D. M., Shousha S., O'Hare M. J., Lu X. High level expression of p27(Kip1) and cychn D1 in some human breast cancer cells: inverse correlation between the expression of p27(Kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 1997; 94: 6380–6385
   PubMed Web of Science ®Google Scholar
• Gammeltoft S. Peptide hormone action. A practical approach. Peptide Hormone Receptors, K. Siddle, J. C. Hutton. Oxford University Press, Oxford 1990; 1–41
   Google Scholar
• Gray-Bublin J., Rao S., Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res. 1997; 57: 604–609
   PubMed Web of Science ®Google Scholar
• Halaban R. Growth factors and melanomas. Semin. Oncology 1996; 23: 673–681
   PubMed Web of Science ®Google Scholar
• Hengst L., Dulic V., Slingerland J. M., Lees E., Reed S. I. A cell-cycle regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 1994; 91: 5291–5295
   PubMed Web of Science ®Google Scholar
• Kanter-Lewensohn L., Dricu A., Wang M., Wejde J., Kiessling R., Larsson O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res. 1998; 8: 389–397
   PubMedGoogle Scholar
• Katayose Y., Kim M., Rakkar A. N. S., Li Z., Cowan K. H., Seth P. Promoting apoptosis: a novel activity associated with the cyclin dependent kinase inhibitor p27. Cancer Res. 1997; 57: 5441–5445
   PubMed Web of Science ®Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit. Rev. Oncol./Hematol. 1996; 22: 197–212
   PubMed Web of Science ®Google Scholar
• Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 1997; 3: 231–234
   PubMed Web of Science ®Google Scholar
• Morgan D. O. Cyclin dependent kinases: engines, clocks and microprocessors. Annu. Rev. Cell Dev. Biol. 1997; 13: 261–291
   PubMed Web of Science ®Google Scholar
• Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. p27 expression and gastric carcinoma. Nature Med. 1997; 3: 593
   PubMed Web of Science ®Google Scholar
• Mouriaux F., Casagrande F., Pillaire M. J., Manenti S., Malecaze F., Darbon J. M. Different expression of G1 cyclins and cyclin-dependent inhibitors in normal and transformed melanocytes. Invest. Ophthalmol. Vis. Sci. 1998; 39: 876–884
   PubMed Web of Science ®Google Scholar
• Poon R. Y. C., Toyoshima H., Hunter T. Redistribution of the cdk inhibitor p27 between different cyclin-cdk complexes in the mouse fibroblast cell cycle and in cells arrested with Lovastatin or ultraviolet irradiation. Mol. Biol. Cell 1995; 6: 1197–1213
   PubMed Web of Science ®Google Scholar
• Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 1997; 3: 222–225
   PubMed Web of Science ®Google Scholar
• Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulinlike growth factor receptor. Cancer Res. 1994; 54: 4848–4850
   PubMed Web of Science ®Google Scholar
• Resnicoff M., Burgaud J.-L., Rotman H. L., Abraham D., Baserga R. Correlation between apoptosis, tumor-igenesis and levels of insulin-like growth factor 1 receptors. Cancer Res. 1995a; 55: 3739–3741
   PubMed Web of Science ®Google Scholar
• Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H. L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor receptor protects tumor cells from apoptosis? in vivo. Cancer Res. 1995b; 55: 2463–2469
   PubMed Web of Science ®Google Scholar
• Roberts C. J., Koff A., Polyak K., Firpo E., Collins S., Ohtsubo M., Massagué J. Cyclins, cdks, and cyclin kinase inhibitors. Cold Spring Harbor Symposia on Quantitative Biology 1994; 59: 31–38
   PubMedGoogle Scholar
• Sherr C. J. G1 phase progression: cycling on cue. Cell 1994; 79: 551–555
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Devel. 1995; 9: 1149–1163
   PubMed Web of Science ®Google Scholar
• Singh S. P., Lipman J., Goldman H., Ellis F. H., Jr., Aizenman L., Cangi M. G., Signoretti S., Chiaur D. S., Pagano M., Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998; 58: 1730–1735
   PubMed Web of Science ®Google Scholar
• Slingerland J. M., Hengst L., Pan C., Alexander D., Stampfer M., Reed S. A novel inhibitor of cyclin-cdk activity detected in TGF-ß-arrested epithelial cells. Mol. Cell. Biol. 1994; 14: 3683–3694
   PubMed Web of Science ®Google Scholar
• Wang X., Gorospe M., Huang Y., Holbrook N. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997; 15: 2991–2997
   PubMed Web of Science ®Google Scholar
• Waechter C. J., Lennarz W. J. The role of polyprenollinked sugars in glycoprotein synthesis. Ann. Rev. Biochem. 1976; 45: 95–112
   PubMed Web of Science ®Google Scholar
• Werner H., Le Roith D. The insulin-like growth factor-1 receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Oncogenesis 1997; 8: 71–92
   Web of Science ®Google Scholar
• Werner H. Dysregulation of the type I IGF receptor as a paradigm in tumor progression. Mol. Cell. Endocrinol. 1998; 141: 1–5
   PubMed Web of Science ®Google Scholar
• Yamamoto H., Soh J.-W., Shirin H., Xing W.-Q., Lim J. T. E., Yao Y., Slosberg E., Tomita N., Schieren I., Weinstein I. B. Comparative effects of over-expression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene 1998; 18: 103–115
   Web of Science ®Google Scholar
• Yang R. M., Naitoh J., Murphy M., Wang H. J., Phillipson J., de Kernion J. B., Loda M., Renter R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 1998; 159: 941–945
   PubMed Web of Science ®Google Scholar